6:19 PM
 | 
Jul 15, 2015
 |  BC Extra  |  Company News

Canbridge gains China rights to APG101

Apogenix GmbH (Heidelberg, Germany) granted Canbridge Life Sciences Ltd. (Beijing, China) exclusive rights to APG101 in China, Macao and Hong Kong to treat glioblastoma multiforme (GBM), with options in additional indications.

Apogenix CEO Thomas Hoeger told BioCentury the company intends to start Phase III trials of the compound next...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >